Andrew Powell

Board Chairman, Landec Corporation

Andrew Powell, has more than 27 years in the biotechnology and pharmaceutical industry and is currently part of the Aclaris Board of Trustees. He most recently served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. from May 2015 until its acquisition by Pfizer, Inc. Prior to Medivation, Mr. Powell served as Executive Vice President, General Counsel and Corporate Secretary of InterMune, Inc. where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) and played a leadership role in InterMune’s acquisition by Roche Holdings AG.

Earlier in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter International, Inc., where he was instrumental in a series of transactions that established Baxter throughout Asia. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals, Inc. as a leader in dermatology before its acquisition by Galderma Pharma S.A. Mr. Powell then served as Senior Vice President and General Counsel at ImClone Systems, Inc., where he helped the company grow beforeplayingakeyroleinitssaletoEliLilly. ImmediatelypriortojoiningInterMune,hewas Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics, Inc. through its successful sale to Chiesi Farmaceutici S.p.A.

Mr. Powell holds a Bachelor of Arts degree from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.